RVU120 Rollover Study

NCT06987058 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Acute Myeloid Leukaemia (AML)
High-risk Myelodysplastic Syndrome

Interventions

DRUG: RVU120

Sponsor

Ryvu Therapeutics SA